Sector Guides
Pharma Exports from India: Compliance Checklist for 15 Markets
US FDA, EU GMP, WHO prequalification, COPP, drug master files. What you need for each destination. Plus common rejection reasons at customs.
By Aaryan Kakani · · 8 min read
India's Pharma Export Landscape
Indian pharmaceutical exports crossed USD 30 billion in FY 2025-26, cementing the country's position as the world's largest supplier of generic medicines. India manufactures over 60,000 generic brands across 60 therapeutic categories and supplies roughly 20% of global generic drug volume by quantity. Indian pharma companies hold more USFDA-approved manufacturing facilities outside the United States than any other country.
The "pharmacy of the world" tag carries real weight: India supplies 50-80% of the global demand for anti-retrovirals, anti-malarials, and vaccines procured through international agencies like UNICEF, the Global Fund (GFATM), and PEPFAR. Over 40% of US generic prescriptions and roughly 25% of all medicines consumed in the UK are manufactured in India.
| Metric | Value (FY 2025-26) |
|---|---|
| Total pharma exports | USD 30.2 billion |
| Share of global generic supply (by volume) | ~20% |
| USFDA-approved facilities in India | 800+ |
| WHO-GMP certified sites | 2,000+ |
| Key export segments | Formulations (75%), APIs (20%), Biologics (5%) |
| Top destinations (by value) | USA, EU, UK, South Africa, Nigeria |
| Pharma SEZs operational | 12 (Hyderabad, Ahmedabad, Vizag, etc.) |
However, pharma is one of the most heavily regulated export sectors. A single missing document can hold an entire container at port for weeks. Every destination country has its own drug regulatory authority, its own registration pathway, and its own GMP inspection requirements. The compliance burden scales with the number of markets you serve. This checklist is designed to give you a structured view of what each market demands, so you can plan registrations and documentation well ahead of your first shipment.
Universal Requirements (Every Market)
Before worrying about destination-specific filings, every Indian pharma exporter must have the following baseline documents in place. These are issued by Indian authorities and are required (or referenced) by virtually every importing country's regulator.
Baseline Document Checklist
- Drug Master File (DMF). A confidential dossier containing the complete manufacturing and quality information for an API or finished dosage form. Filed with the destination regulator (e.g., USFDA Type II DMF for APIs). The DMF allows the regulator to review manufacturing details without disclosing proprietary information to the finished dosage form manufacturer.
- Certificate of Pharmaceutical Product (COPP). Issued by CDSCO (Central Drugs Standard Control Organisation), this certifies that the product is authorized for sale in India, the manufacturing facility is licensed, and it is subject to periodic inspections. The COPP follows the WHO-recommended format and is accepted by most regulatory authorities worldwide.
- GMP Certificate. Issued by the State Drug Controller (for domestic GMP) or by CDSCO (for WHO-GMP). Confirms the manufacturing facility meets Good Manufacturing Practice standards. Many markets (EU, Australia, Brazil) require their own GMP inspections in addition to the Indian certificate.
- Free Sale Certificate (FSC). Confirms that the pharmaceutical product is freely sold in the Indian domestic market without restriction. Issued by CDSCO. Required by many African, Middle Eastern, and ASEAN regulators as part of the registration dossier.
- Export NOC from CDSCO. A No Objection Certificate required for each export consignment of pharmaceutical products. Applied for online via the CDSCO Sugam portal. Processing time is typically 5-10 working days. Without this, customs will not allow the shipment to leave India.
In addition to the documents above, you will need standard export documentation common to all goods exports from India: a valid IEC (Import Export Code) from DGFT, an AD Code registration with your bank, a shipping bill filed on ICEGATE, a Certificate of Origin (non-preferential or preferential depending on the FTA status), and complete export documentation (commercial invoice, packing list, Bill of Lading/AWB).
Market-Specific Requirements (15 Markets)
Each destination market has its own drug regulatory authority with unique registration pathways, GMP inspection requirements, and documentation standards. The table below summarizes the key requirements for 15 major pharma export destinations. Use it as a planning tool. Timelines and costs can vary significantly, so engage with a regulatory consultant early.
| Market | Regulatory Authority | Key Requirements |
|---|---|---|
| USA | USFDA | FDA establishment registration + drug listing; ANDA (generics) or NDA (new drugs) filing; FDA facility inspection (pre-approval and routine); 510(k) clearance for medical devices; DSCSA serialization for track-and-trace compliance |
| EU (27 states) | EMA / National Agencies | EU GMP certificate (inspected by EU member state authority); CEP (Certificate of Suitability to European Pharmacopoeia) for APIs; Marketing Authorization via centralized (EMA), decentralized, or mutual recognition procedure; EU Falsified Medicines Directive (FMD) serialization |
| UK | MHRA | MHRA establishment registration; UK Marketing Authorization (separate from EU post-Brexit); UK GMP certificate (MHRA inspection); UK-specific labeling and PIL (Patient Information Leaflet) requirements |
| Japan | PMDA | PMDA pre-approval consultation; J-GMP compliance (MF registration); CTD (Common Technical Document) filing in eCTD format; Japanese-language labeling; Marketing Authorization Holder (MAH) must be a Japanese entity |
| Australia | TGA | TGA registration on the ARTG (Australian Register of Therapeutic Goods); PIC/S-compliant GMP (TGA inspects Indian sites); Sponsor must be an Australian entity; Certificate of GMP Compliance required |
| Brazil | ANVISA | ANVISA product registration; ANVISA GMP inspection of Indian manufacturing site (mandatory pre-approval); COPP from CDSCO required; Portuguese-language labeling and packaging inserts |
| Canada | Health Canada | Drug Establishment License (DEL); Notice of Compliance (NOC) for drug approval; ANDS (Abbreviated New Drug Submission) for generics; Health Canada GMP inspection; bilingual (English + French) labeling |
| South Africa | SAHPRA | SAHPRA registration (backlog of 2-4 years common); CTD dossier in eCTD format; WHO-GMP or PIC/S GMP certificate; COPP and FSC from CDSCO; Zone IVa stability data |
| Nigeria | NAFDAC | NAFDAC registration and product listing; NAFDAC facility inspection (or acceptance of WHO-GMP certificate); COPP required; Full quantitative formula disclosure; local agent/representative required |
| Kenya | PPB (Pharmacy and Poisons Board) | PPB product registration; WHO-GMP certificate or PIC/S GMP; COPP and FSC from CDSCO; Zone IVa stability studies; local technical representative required |
| UAE | MOHAP / DHA / HAAD | MOHAP registration for federal market; DHA registration for Dubai; HAAD registration for Abu Dhabi; GMP certificate (WHO, PIC/S, or destination-country inspected); stability data for Zone IVa/IVb |
| Saudi Arabia | SFDA | SFDA product registration via the SFDA e-portal; GMP compliance (SFDA may inspect or accept PIC/S member inspections); Arabic-language labeling; Gulf Central Committee for Drug Registration (GCC-DR) mutual recognition possible |
| Russia | Minzdrav (via EAEU) | EAEU (Eurasian Economic Union) registration; GMP inspection by Russian inspectorate; Clinical trial data sometimes required; Russian-language dossier and labeling; local authorized representative required |
| WHO Prequalification | WHO PQP | WHO Prequalification programme dossier (based on ICH CTD); WHO GMP inspection; bioequivalence studies for generics; essential for UNICEF, GFATM, and PEPFAR procurement tenders; not a market but a critical pathway for institutional sales |
| ASEAN (10 states) | National Agencies | ASEAN Common Technical Dossier (ACTD) format accepted across member states; individual national registration still required; PIC/S GMP increasingly accepted; COPP from CDSCO; stability data for Zone IVa/IVb climatic conditions |
Regulated vs. Semi-Regulated Markets
Pharma export destinations are often classified by the stringency of their regulatory requirements:
- Highly regulated (USA, EU, UK, Japan, Australia, Canada). Require full dossier review, bioequivalence studies, pre-approval GMP inspection by the destination regulator, and ongoing periodic inspections. Timelines: 2-5 years from first filing to first shipment. Higher barriers but higher margins.
- Semi-regulated (Brazil, Russia, South Africa, Saudi Arabia, UAE). Require registration dossiers and often conduct their own GMP inspections, but may accept reference approvals from stringent regulators. Timelines: 1-3 years.
- Emerging/ROW (most of Africa, parts of Asia, Latin America). Typically accept WHO-GMP certificates, COPP, and FSC from CDSCO as the primary evidence of quality. Registration timelines: 6-18 months. Lower margins but higher volumes.
Common Rejection Reasons at Destination Customs
Even with all registrations in place, pharma shipments can be held, rejected, or destroyed at the destination port. These are the most common reasons Indian pharma shipments face problems at customs:
Missing or Mismatched Certificate of Analysis (CoA)
The CoA must correspond exactly to the batch being shipped. Common errors: CoA references a different batch number than what is on the carton labels, CoA is expired (test date is too old relative to the shelf life), or CoA is missing altogether because it was packed inside the container instead of being sent with the shipping documents. Always send the CoA with the commercial documents and ensure batch numbers match across the CoA, packing list, commercial invoice, and carton labels.
Temperature Excursion During Transit
Cold-chain and controlled-room-temperature products must maintain their specified storage conditions throughout transit. A data logger showing even a brief temperature breach can result in the entire shipment being rejected or destroyed. Use validated shipping containers, redundant data loggers, and a clear temperature excursion protocol. For sea freight, reefer containers with real-time GPS temperature monitoring are increasingly standard for regulated markets.
Labeling Non-Compliance
Each market has specific labeling requirements: local-language text (French for Canada, Portuguese for Brazil, Arabic for Saudi Arabia, Japanese for Japan), specific dosage unit formats (mg vs mcg), expiry date format (MM/YYYY vs YYYY-MM), barcode standards, and PIL (Patient Information Leaflet) inclusion. Products labeled only in English will be rejected in most non-English-speaking markets. Get your label artwork reviewed by a local regulatory consultant before printing.
Incorrect HS Code Classification
Pharmaceutical products span HS Chapters 28, 29, 30, and 38 depending on whether they are APIs, intermediates, formulations, or diagnostic reagents. An incorrect HS code can trigger the wrong duty rate, trigger additional inspections (if the code falls under a restricted category), or cause a mismatch between your DGFT filings and the destination customs declaration. Use the 8-digit HS code specific to the destination country and verify it against the product's actual composition, not just its trade name.
Serialization Failures
The US (DSCSA), EU (FMD), and several other markets now mandate unit-level serialization with unique identifiers on each saleable unit. If serial numbers are not uploaded to the destination's verification system before the shipment arrives, or if the 2D DataMatrix barcode is unreadable, the shipment will be held. Ensure your serialization system (typically SAP ATTP or TraceLink) is integrated with the destination verification hub before shipping.
Export Incentives for Pharma
Indian pharma exporters are eligible for several government incentives that can meaningfully improve margins. Pharma products are covered under the RoDTEP scheme, qualify for Duty Drawback on imported raw materials and intermediates, and can use the EPCG scheme for duty-free import of manufacturing equipment.
RoDTEP (Remission of Duties and Taxes on Exported Products)
Pharma products under HS Chapter 30 (medicaments) are eligible for RoDTEP benefits ranging from 0.5% to 2.5% of FOB value, depending on the specific HS code. APIs under Chapter 29 also qualify at similar rates. Credits are issued as transferable duty scrips via ICEGATE and can be used against future customs duty payments or sold on the market.
[Duty Drawback](/resources/duty-drawback)
Pharma manufacturers who import raw materials, APIs, intermediates, or packaging materials can claim Duty Drawback on the customs duties paid on those inputs. All Industry Rates (AIR) for common pharma HS codes range from 1.5% to 4% of FOB value. If your actual duty incidence is higher, apply for a Brand Rate through your jurisdictional customs office. Duty Drawback can be claimed simultaneously with RoDTEP.
[EPCG (Export Promotion Capital Goods) Scheme](/resources/epcg-scheme)
Pharma manufacturers can import capital goods (manufacturing equipment, testing instruments, packaging machinery, HVAC systems, clean room equipment) at zero customs duty under EPCG. The obligation is to export 6 times the duty saved over 6 years. Particularly valuable for companies setting up new WHO-GMP or USFDA-compliant manufacturing lines, where equipment imports can run into crores.
Advance Authorisation
Allows duty-free import of raw materials, intermediates, and packaging materials that are physically incorporated in the export product. Unlike Duty Drawback (which is a refund after payment), Advance Authorisation provides upfront duty exemption. Requires a Standard Input Output Norm (SION) or an ad-hoc norm fixation from DGFT. Useful for large-volume formulation manufacturers importing APIs.
Frequently Asked Questions
What documents does every Indian pharma exporter need regardless of destination?
Five baseline documents: a Drug Master File (DMF) for each product, a Certificate of Pharmaceutical Product (COPP) from CDSCO, a GMP certificate (State Drug Controller or WHO-GMP from CDSCO), a Free Sale Certificate, and an Export NOC from CDSCO for each shipment. In addition, you need standard export documents. IEC, AD Code, shipping bill, Certificate of Origin , commercial invoice, and packing list.
How long does USFDA registration take for an Indian pharma company?
Establishment registration and drug listing can be done in a few weeks. However, an ANDA filing for a generic drug typically takes 18-30 months for approval, and an FDA facility inspection must be passed before you can ship commercially. The total timeline from initial filing to first export is usually 2-4 years. Expedited pathways exist for drugs on the FDA shortage list or for PEPFAR-eligible products.
What are the most common reasons pharma shipments get rejected at destination customs?
The top four: missing or mismatched Certificate of Analysis (batch number discrepancy), temperature excursion during transit (data logger shows a breach), labeling non-compliance (missing local-language text, wrong date format, absent PIL), and incorrect HS code classification. Serialization failures under DSCSA (US) and FMD (EU) are an increasingly common fifth reason. Read our export documentation guide to ensure your paperwork is complete.
Update history
- First published.